Crown Grows With Keri From GSK, Which Says Little On Consumer Pending JV Launch With Pfizer

Sales to Crown Labs didn't breach GSK's attention when it reported its Q1 results, with its consumer health discussion limited to general figures on regions and product categories. Pfizer offered even less about its consumer health operations and plans with its Q1 report.For Crown Labs, landing North American rights to Keri brand marks another step toward offering comprehensive skin care selection.

Crown Laboratories, Inc offices
Crown Labs lands North American rights to the Keri brand, its second deal with GSK in five months.

GlaxoSmithKline PLC and Pfizer Inc.'s planned consumer health joint venture will have one less product to manage as GSK continues offloading non-core brands with the sale of the Keri line to skin care product marketer Crown Laboratories Inc.

The April 30 deal didn't make GSK's presentation for its 2019 first-quarter results a day later. The UK big pharma's...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Archive

More from HBW Insight